T-cell lymphoma registry study
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a specific type of T-cell or NK-cell lymphoma (your doctor can confirm which one).
- You have a tumor biopsy sample (either already stored or one that can be taken) to study.
- If you have mycosis fungoides, anaplastic large cell lymphoma of the skin, or acral CD8+ T-cell lymphoma, you must be getting systemic treatment (medicine that works throughout the body).
- You agree to allow researchers to collect your health information and follow your progress over time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
This study collects medical information and blood samples from people with Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases to better understand how these conditions progress and respond to treatment. It includes a retrospective part (looking back at medical records) and a prospective part (following people forward in time).
This early-phase study tests a combination treatment—chemo, immunotherapy, and a donor stem cell transplant—for certain aggressive NK/T-cell lymphomas. It may help patients who have advanced-stage disease by trying to improve long-term control of the cancer.
This study, run by Massachusetts General Hospital, is collecting information from people around the world who have certain types of T-cell or NK-cell lymphoma. It aims to learn more about these cancers and how they are managed.
This trial is testing a combination of two drugs for T-cell lymphoma that has returned after prior treatment. The drugs are belinostat (given as an infusion) plus either azacitidine or pralatrexate. The goal is to see if this combination can help control the lymphoma and for how long.
This is an observational registry that collects real-world information about people newly diagnosed with peripheral T-cell or certain NK-cell lymphomas. It does not test a new drug, but it helps researchers understand patterns of disease and care, which can guide future studies.
Hear when a new T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.